Want to see TNON full AI Analyst Report?
TNON Stock Chart & Stats
$5.21
>-$0.01(-3.00%)
At close: 4:00 PM EDT
$5.21
>-$0.01(-3.00%)
Day’s Range― - ―
52-Week Range$3.68 - $50.40
Previous Close$0.19
Volume460.08K
Average Volume (3M)2.38M
Market Cap
$2.98M
Enterprise Value$11.30
Total Cash (Recent Filing)$1.68M
Total Debt (Recent Filing)$5.68M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Nov 18, 2026EPS Estimate
-5.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-46.30
Shares Outstanding667,047
10 Day Avg. Volume6,074,450
30 Day Avg. Volume2,380,900
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.39
Price to Sales (P/S)1.78
P/FCF Ratio-0.64
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.00Price Target Upside91.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-23.75
Revenue Forecast (FY)$6.40M
Bulls Say, Bears Say
Bulls Say
Revenue And Gross Margin ExpansionRapid procedure-driven revenue growth and materially higher gross margins indicate improving commercial traction and production economics. If sustained, better scale and field productivity could strengthen the company’s unit economics as Catamaran and SImmetry+ adoption expands.
FDA Clearance And Product EconomicsThe regulatory clearance supports continued commercialization while reusable instruments are expected to reduce per-procedure costs beginning in Q3. Lower procedure costs may improve physician and facility adoption, protect gross margins, and enhance the platform’s competitive positioning.
Commercial And R&D ExpansionHigher training activity, new sales infrastructure, distributor expansion, and multiple product programs create a broader commercialization engine. These investments can support surgeon adoption and diversify future growth, provided execution converts training and innovation into recurring procedures.
Bears Say
Persistent Operating LossesRevenue and gross profit growth have not yet translated into operating leverage. Persistent losses suggest the current cost base remains too large for the revenue scale, creating ongoing dependence on growth acceleration, expense discipline, or additional financing.
Cash Burn And Weak CapitalizationNegative cash generation and negative equity limit financial flexibility and indicate that operations are not self-funding. Debt obligations and continuing losses increase refinancing and dilution risk, while future capital raises may be needed to sustain commercialization and development.
Dependence On Procedure AdoptionThe business depends on converting surgeon education and commercial expansion into sustained SI joint procedures. Adoption can be constrained by training cycles, sales execution, reimbursement access, and seasonality, making the growth outlook sensitive to several external and operational factors.
Tenon Medical, Inc. News
TNON FAQ
What was Tenon Medical, Inc.’s price range in the past 12 months?
Tenon Medical, Inc. lowest stock price was $3.68 and its highest was $50.40 in the past 12 months.
What is Tenon Medical, Inc.’s market cap?
Tenon Medical, Inc.’s market cap is $2.98M.
When is Tenon Medical, Inc.’s upcoming earnings report date?
Tenon Medical, Inc.’s upcoming earnings report date is Nov 18, 2026 which is in 75 days.
How were Tenon Medical, Inc.’s earnings last quarter?
Tenon Medical, Inc. released its earnings results on Aug 13, 2026. The company reported -$12.35 earnings per share for the quarter, missing the consensus estimate of -$8.4 by -$3.95.
Is Tenon Medical, Inc. overvalued?
According to Wall Street analysts Tenon Medical, Inc.’s price is currently Undervalued.
Does Tenon Medical, Inc. pay dividends?
Tenon Medical, Inc. does not currently pay dividends.
What is Tenon Medical, Inc.’s EPS estimate?
Tenon Medical, Inc.’s EPS estimate is -5.62.
How many shares outstanding does Tenon Medical, Inc. have?
Tenon Medical, Inc. has 667,047 shares outstanding.
What happened to Tenon Medical, Inc.’s price movement after its last earnings report?
Tenon Medical, Inc. reported an EPS of -$12.35 in its last earnings report, missing expectations of -$8.4. Following the earnings report the stock price went down -13.423%.
Which hedge fund is a major shareholder of Tenon Medical, Inc.?
Currently, no hedge funds are holding shares in TNON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tenon Medical, Inc.
Tenon Medical, Inc., a medical device company, engages in the development of implant for the treatment of severe lower back pain in the United States. The company offers Catamaran SI-Joint Fusion System, an invasive approach to the sacroiliac joint (SI Joint) using a titanium implant for treatment of the most common types of SI Joint disorders that cause lower back pain. It also provides Catamaran Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, transfixing the SI Joint along its longitudinal axis. Tenon Medical, Inc. was incorporated in 2012 and is headquartered in Los Gatos, California.
TNON Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents strong operational momentum with record second-quarter revenue, substantial gross profit and margin expansion, FDA clearance for Catamaran, an advancing R&D pipeline, and a $4.2M capital raise to extend runway. These positives are tempered by continued operating losses, higher operating expenses, non-cash interest expenses increasing net loss, and a diminished quarter-end cash balance. However, management has clear near-term catalysts (product launches, reusable instrumentation benefits beginning in Q3, training center momentum) that are likely to drive further progress.View all TNON earnings summariesTNON Stock 12 Month Forecast
Average Price Target
$10.00
▲(91.94% Upside)
Technical Analysis
Strata Skin Sciences
―
Lifeward
―
enVVeno Medical
―
PAVmed
―
Heart Test Laboratories, Inc.
―
Ownership Overview
10.70% Insiders
0.77% Mutual Funds
0.06% Other Institutional Investors
88.06% Public Companies and
Individual Investors